Dr M. Trenton
-
Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study
“`html Study on PSMA-Targeting Radionuclide Therapy for Prostate Cancer Purpose: Assess PSMA-targeting radionuclide therapy for prostate cancer Evaluate dosimetry and radiation toxicity Explore PSA response in metastatic castration-resistant prostate cancer (mCRPC) patients Methods: Patients with PSMA-positive tumors enrolled after PET/CT scan Five patients received [177Lu]Lu-P17-087 and four received [177Lu]Lu-P17-088 Imaging and dosimetry evaluations were performed […] ➡️➡️➡️
